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Purpose: The purpose of this study was to examine the impact of radiation therapy on quality of
life (QOL) of breast cancer patients during and until 1 year after radiation therapy treatment.
Methods and materials: Thirty-nine breast cancer patients treated with breast-conserving surgery
were enrolled in a prospective study before whole breast radiation therapy (50 Gy plus a 10-Gy
boost). No patient received chemotherapy. Data were collected before, at week 6 of radiation therapy,
and 6 weeks and 1 year after radiation therapy. The primary outcome variable was quality of life
(QOL), measured by Medical Outcomes Study 36-Item Short Form Version 2 (SF-36). Risk factors
potentially associated with total SF-36 scores and its physical and mental health component summary
scores were also examined, including age, race, marital status, smoking history, menopausal status,
endocrine treatment, cancer stage, sleep abnormalities (assessed by the Pittsburgh Sleep Quality
Index), and perceived stress levels (assessed by the Perceived Stress Scale). Mixed effect modeling
was used to observe QOL changes during and after radiation therapy.
Results: Total SF-36 scores did not change signiﬁcantly during and up to 1 year after radiation
therapy compared with baseline measures. Nevertheless, increased body mass index (BMI) and
increased perceived stress were predictive of reduced total SF-36 scores over time (PZ .0064, and
P < .0001, respectively). In addition, increased BMI was predictive of reduced physical component
summary scores of the SF-36 (P Z .0011), whereas increased perceived stress was predictive of
worse mental component summary scores (P < .0001). Other proposed potential risk factors
including skin toxicity from radiation therapy were not signiﬁcant.
Conclusions: Radiation therapy did not worsen QOL in breast cancer patients. However, pre-
radiation therapy patient characteristics including BMI and perceived stress may be used to identify
women who may experience decreased physical and mental function during and up to 1 year after
radiation therapy.
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malignancy diagnosed in women in the United States, with
1 in 8 women developing breast cancer in her lifetime.1
Localized disease accounts for 61% of all breast cancers
diagnosed in the United States, and the 5-year survival rate
for this population approaches 98%.2 Given the large
number of breast cancer survivors, increasing attention is
being paid to the impact of cancer treatments on quality of
life (QOL), because it represents a potentially signiﬁcant
public health concern.
Previous studies have shown that chemotherapy
signiﬁcantly worsens QOL in breast cancer patients.3,4 In
these studies, the Medical Outcomes Study 36-Item Short
Form Version 2 (SF-36), which has been validated in a
population of healthy women, has been one of the most
commonly used instruments to assess QOL. Although
chemotherapy has been consistently shown to worsen SF-
36 scores and decrease QOL, few studies have examined
the impact of breast radiation therapy (RT) on QOL.
Research on breast RT has been limited by cross-sectional
design and by the inclusion of patients treated in a het-
erogeneous manner (eg, lumpectomy, mastectomy, with
or without prior chemotherapy).5-10
Radiation therapy after breast-conserving surgery is
the standard of care for the majority of breast cancer
patients, because RT signiﬁcantly reduces breast cancer
recurrence.11 Nevertheless, many women will forego RT
from “fearing the unknown,” “getting burnt,” “damaging
internal parts,” and “anticipating tiredness.”12 Fear of how
RT may impact QOL both during and after RT may
decrease compliance with treatment and, ultimately, in-
crease the risk of cancer recurrence.11,13 However, QOL
changes during and after RT have not been prospectively
assessed with the SF-36 instrument in a longitudinal study
of homogeneously treated patients, and risk factors for
poor QOL over time have not been studied. Thus, the
purpose of this study was to explore QOL changes and
risk factors for poor QOL in early breast cancer patients
before, during, and after RT following breast-conserving
surgery in the absence of prior exposure to chemo-
therapy treatment.Methods and Materials
Study design
Subjects were recruited from Emory University
Department of Radiotherapy Oncology from March 2010
to March 2013. After receiving breast-conserving surgery,
stage 0-II breast cancer patients who were recommended
whole-breast RT were approached for enrollment. All
enrolled subjects provided written informed consent, andall procedures were a priori approved by the Emory
University Institutional Review Board.
Patients were excluded if they received chemotherapy
for their breast cancer. They were also excluded for co-
morbid conditions including uncontrolled cardiovascular,
metabolic, pulmonary, or renal disease, pregnancy, and
history of major psychiatric disorder, such as schizo-
phrenia, bipolar disorder, or substance abuse/dependence,
which may impact QOL.
Based on previous QOL studies, pre-RT patient and
tumor characteristics, including age, body mass index
(BMI), race (Caucasian vs African American), marital
status (married [married or living with signiﬁcant others]
versus unmarried [single, divorced, or widowed]),
smoking history (no vs yes), menopause status (pre/peri
vs post), cancer stage (0 vs 1), and skin toxicity from
RT, were recorded to determine their impact on
QOL.6,9,14-16
RT
All patients were treated with 50 Gy to the whole
breast followed by a 10-Gy boost to the lumpectomy
cavity given in 2-Gy fractions with 6-MV photons and/or
18-MV photons using standard tangential ﬁeld-in-ﬁeld
technique to promote dose homogeneity. Radiation ther-
apy plans were generated according to the International
Commission on Radiotherapy Units-50 guidelines.17
Patients were assessed before (within the week before
starting RT), at week 6 (ﬁrst day of boost treatment), 6
weeks, and 1 year post-RT. Endocrine therapy was pre-
scribed to patients who were hormone receptor positive
and was not initiated until after RT completion. Skin
toxicity was graded by physicians at each time point using
the Radiation Therapy Oncology Group grading criteria.
Behavioral measures
Quality of life was measured by the SF-36, which is
one of the most commonly used generic health-related
QOL questionnaires, with well-documented validity and
reliability in various populations,18-20 including patients
with breast cancer.21,22 There are 8 multi-item subscales:
physical functioning, role limitations because of physical
health, bodily pain, general health perceptions, vitality,
social functioning, role limitations from emotional prob-
lems, and mental health. The scores for the subscales
range from 0 to 100, with 100 being the most favorable
score. The US general population norm scores are pub-
licly available for the subscales.23 In addition, the scores
from the 8 subscales can be combined into 2 component
summary scores reﬂecting physical and mental health.24
The 2 component summary scores are standardized with
a mean score of 50 and 1 standard deviation of 10. A
score of 60 signiﬁes 1 standard deviation above the
Table 1 Demographic and clinical characteristics (NZ 39)
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deviation below the general population mean. A total
QOL score was calculated as the average of the physical
health component summary and the mental health
component summary scores, with higher scores indicating
better QOL.
Previous studies have indicated that sleep and stress
are major behavioral factors that may impact QOL.16,25,26
The Pittsburgh Sleep Quality Index (PSQI) was used to
assess subjective sleep quality and disturbances over the
prior month in our subjects. This questionnaire has high
internal consistency and test-retest reliability and can
distinguish good sleepers from bad sleepers among breast
cancer patients.27,28 The PSQI contains 15 multiple-
choice items and 4 write-in items, which generate
scores for 7 subscales: duration of sleep, sleep distur-
bance, sleep latency, day dysfunction from sleepiness,
sleep efﬁciency, overall sleep quality, and medications for
sleep. The score for each subscale ranges from 0 (no
difﬁculty) to 3 (severe difﬁculty). The 7 subscale scores
are summed to produce a global score ranging from 0 to
21. A PSQI global score greater than 5 is considered to be
suggestive of signiﬁcant sleep disturbance.27
The Perceived Stress Scale (PSS) is one of the most
widely used instruments to assess stress and has been
previously used in patients with breast cancer.29,30 The
PSS is a well-veriﬁed questionnaire for measuring
nonspeciﬁc perceived stress that exceeds a person’s
coping abilities in the past month.31 Ten items are
included in the PSS, and each item is scored by using a 5-
point Likert scale ranging from 0 to 4, with 0 representing
never and 4 representing very often. Higher scores mean
more perceived stress.
The SF-36, PSQI, and PSS assessments were per-
formed at all 4 study time points.Variables Mean  SD or N (%)
Age (y) 59.38  9.24
BMI 30.66  7.23
Race
Caucasian 24 (62)
African American 15 (38)
Marital statusa
Married 18 (46)










BMI, body mass index; SD, standard deviation.
a Married includes patients married or living as married; not
married includes patients who are single, separated, divorced, or
widowed.Data analysis
Descriptive statics were used for demographic and
clinical characteristics. Mean and standard deviation were
presented for categorical variables, and frequency and
percentages were used for continuous variables. Mixed
effect modeling was generated to assess the change in
trajectories of QOL over time and the impact of variables
of interest on QOL over time. Variables included in the
model were sleep, stress, age, BMI, race, marital status,
smoking history, menopause status, endocrine treatment,
cancer stage, and skin toxicity from RT. Only variables
that showed a signiﬁcance level of 0.10 on bivariate an-
alyses were included in the ﬁnal regression model. In
addition, one-half standard deviation from normal mean
values of SF-36 scores was used in this study as a mini-
mal clinically important difference.32 All analyses were
done using SAS 9.3 (SAS Institute, Inc., Cary, NC) with a
signiﬁcance level of 0.05.Results
Patients’ characteristics
Thirty-nine patients were enrolled in the study
following breast-conserving surgery. Demographic and
clinical characteristics of participating subjects are listed
in Table 1. The average BMI was 30.66, with 23% of
patients having a BMI below 25, 36% having a BMI
between 25 and 30, and 41% with a BMI above 30. Sixty-
two percent of participants were Caucasian and 54% were
unmarried (deﬁned as single, separated, divorced, or
widowed). Forty-six percent of subjects had stage 0 breast
cancer, whereas 54% had stage I or II disease. Among the
enrolled subjects, 100%, 97%, 92%, and 64% completed
SF-36 measures at baseline, week 6 of RT, and 6 weeks
and 1 year after RT, respectively.
QOL over time
The total QOL score did not change signiﬁcantly
during or after RT (Table 2). In addition, no change was
observed in the physical or mental health component
summary scores over time. Of the 8 subscales, only the
role physical subscale score exhibited a signiﬁcant
improvement from pre- to post-RT (FZ 5.59, PZ .002).
Post hoc comparisons using least signiﬁcant difference
test revealed that the role physical subscale scores at both
1 year post-RT was signiﬁcantly higher than the pre-RT
and 6 weeks of RT scores (P Z .025 and P Z .008,
respectively).




Week 6 of RT
(n Z 38)
6 weeks after RT
(n Z 36)
1 year after RT
(n Z 32)
Physical functioning 76.28  27.19 74.34  26.54 79.58  27.27 76.56  28.38
Role physicala 66.67  39.87 64.47  38.83 75.00  39.19 86.72  26.17
Bodily pain 71.51  22.67 70.18  22.40 73.61  19.28 70.50  19.78
General health 75.77  17.20 76.21  15.84 75.22  17.08 76.62  16.85
Vitality 65.00  19.40 63.03  22.23 66.94  22.30 66.41  22.69
Social functioning 80.45  21.80 82.23  19.42 86.11  22.51 88.67  23.19
Role emotional 84.62  33.20 86.84  28.52 85.19  31.31 86.46  27.90
Mental health 79.79  15.97 87.79  10.76 85.22  15.32 84.50  16.28
Physical component summary 47.98  10.49 46.12  9.77 48.91  10.49 49.28  9.83
Mental component summary 52.94  8.79 55.76  6.36 54.70  9.92 54.92  9.48
Total score 50.46  6.32 50.94  6.27 51.81  7.13 52.10  6.61
RT, radiation therapy; SD, standard deviation.
a P < .05.
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Patients’ sleep scores did not change signiﬁcantly over
time (PZ .583); however, more than half of the patients had
PSQI scores were >5 at each time point (51%, 47%, 49%,
and 58%, at pre-, week 6, 6 weeks, and 1 year post-RT,
respectively). Patients’ perceived stress levels decreased
signiﬁcantly from pre- to 1 year post-RT (PZ .005).
Risk factors for reduced QOL over time
Table 3 reveals that BMI and perceived stress were the
only variables that were signiﬁcantly associated with total
QOL scores. Patients who had a higher BMI or higher
PSS scores were more likely to have reduced total QOL
scores. In addition, higher BMI was predictive of worse
scores on the physical component summary score of the
SF-36 over time, whereas exhibiting higher perceived
stress was predictive of worse scores on the mental
component summary score. Of note, PSQI scores were
not associated with any QOL scores. Other proposed
potential risk factors, including skin toxicity from RT,
were not signiﬁcant in the ﬁnal model.
Discussion
This is one of the few studies to prospectively evaluate
the effect of RT on the QOL of nonchemotherapy-treated
breast cancer patients before, during, and after RT using
the SF-36 instrument. Given that most studies on QOL in
early breast cancer patients have included subjects treated
with RT and chemotherapy, this study was uniquely
positioned to evaluate the effect of RT alone on the QOL
of early-stage breast cancer patients following breast
conserving surgery.QOL change over time
Radiation therapy does not appear to signiﬁcantly
change patients’ QOL. Patients in our study had relatively
stable QOL with a trend toward better from pre- to 1 year
after RT. That RT may not change QOL has been
demonstrated in several studies using other QOL ques-
tionnaires in cohorts of patients heterogeneously treated
with various systemic regimens consisting of chemo-
therapy and/or endocrine treatment.33-36 For example, a
large phase 3 randomized clinical trial compared early-
stage breast cancer patients receiving postlumpectomy
with or without RT.34 Quality of life, measured by the
European Organization for Research in the Treatment of
Cancer instrument, were identical between treatment arms
within 15 months after surgery. A study with a 15-year
follow-up period also demonstrated that women treated
with surgery and RT had very high QOL assessed by the
European Quality of Life-5 Dimensions, and the patient
scores were comparable to those seen in an otherwise
normal adult female US population.37
Our study found that patients’ role limitations resulting
from physical health, measured by the role physical subscale
of the SF-36, improved signiﬁcantly from pre- to 1 year
post-RT. This improvement indicates that physical health-
related difﬁculties with working or other daily activities
before and during RT, improved over time. Our statistical
analysis further showed that this improvement was specif-
ically signiﬁcant at 1 year post-RT compared with pre-RT
treatment or at week 6 of RT. Ganz and colleagues21 also
assessed role physical using SF-36 for breast cancer patients
from pretreatment until 1 year posttreatment. Similarly, they
found substantial improvements over time for role limita-
tions resulting from physical health.
Overall, our study found that patients’ QOL does not
change signiﬁcantly during and after RT; however,
Table 3 Association between demographic and clinical
characteristics and SF-36 over time
Estimates SE P
SF-36 total score
The ﬁrst model with all variables P < .1
Age 0.02 0.44 .6625
BMI 0.18 2.85 .0067
Marriage: not marrieda 1.83 2.03 .0481
PSS score 0.38 6.14 <.0001
PSQI score 0.21 1.73 .0914
Time: baselineb 1.06 0.70 .4895
Time: 6 weeks of RTb 2.51 1.62 .1130
Time: 6 weeks post-RTb 2.05 1.21 .2342
The ﬁnal model with only variables P < .05
BMI 0.19 0.07 .0064
PSS score 0.41 0.06 <.0001
Physical Component Summary Score
The ﬁrst model with all variables P < .1
BMI 0.42 0.12 .0011
The ﬁnal model with only variables P < .05
BMI 0.42 0.12 .0011
Mental Component Summary Score
The ﬁrst model with all variables P < .1
Age 0.01 0.07 .9447
Marriage: not marrieda 3.35 2.39 .0214
PSS score 0.60 6.61 <.0001
PSQI score 0.23 1.29 .2024
Time: baselineb 1.40 0.75 .4567
Time: 6 weeks of RTb 1.11 0.67 .5051
Time: 6 weeks post-RTb 2.46 1.33 .1893
The ﬁnal model with only variables P < .05
PSS score 0.61 0.09 <.0001
BMI, body mass index; PSQI, Pittsburgh Sleep Quality Index; PSS,
perceived stress scale; RT, radiation therapy; SE, standard error;
SF-36, Medical Outcomes Study 36-Item Short Form.
a The reference group was married.
b The reference group was the time at 1 y post-RT.
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experience from their physical health improves remark-
ably during this period. Previous studies have shown that
patients’ fear of RT decreases the compliance of RT,
which may eventually reduce the rate of local control and
long-term survival.11,13 Our ﬁndings indicate that patients
who undergo RT do not experience a worse QOL
resulting from the treatment and provide evidence for
clinicians to share with patients who may anticipate sig-
niﬁcant life-changing side effects and poor QOL from RT.Risk factor for QOL over time
Although BMI and perceived stress were signiﬁcant
risk factors for total QOL, the signiﬁcant risk factors for
each of the 2 component summary scores of QOL were
different. BMI was more predictive of reduced physical
function, whereas perceived stress predicted for mentalhealth function. This ﬁnding indicates the distinctive
components underlying physical and mental health might
lead to the divergent risk factor proﬁles for these different
QOL components. Carver and colleagues14 found similar
results, which showed different components of QOL may
have different types of predictors including demographic,
medical, and psychosocial patient characteristics.
Our study indicates that BMI is a signiﬁcant inde-
pendent risk factor for QOL, and speciﬁcally for physical
function. Similar ﬁndings have been presented in previous
studies using either the SF-3616 or different QOL ques-
tionnaires.5 The effect of BMI on physical health may
even last up to 40 months after diagnosis.16 The exact
reason for this relationship is not well documented;
however, higher BMI usually is related to higher inci-
dence of lymphedema and other treatment-related symp-
toms.16 Lower physical activity38 associated with a higher
BMI may also explain poor QOL.
Our data also support the hypotheses that high
perceived stress may contribute to poor QOL, more spe-
ciﬁcally to the mental health component summary score,
during and after breast cancer RT. This relationship has
been shown in many other studies, especially studies
using psychosocial behavioral interventions to reduce
stress.39,40 Although the majority of these studies did not
directly use the perceived stress measurements, they used
measurements related to mental or emotional health for
the outcome measure of stress reduction.
Research has demonstrated that breast cancer patients
with poor sleep quality usually report worse total QOL.6
However, our study showed that sleep problems had
only a trend effect on mental component summary score.
This trend is probably from the relatively small sample
size. In addition, our study did not show any effect of
sleep problems on the physical component summary
score, which is not consistent with other recent studies.
One recent study found that poor sleep quality was most
strongly associated with physical and functional well-
being instead of emotional and family well-being.41
Another group found that poor sleep has an inﬂuence
on both physical and mental health.26 Although all of the
3 studies used the same sleep quality questionnaire, PSQI,
and investigated patients before, during and after treat-
ment, their studies used different QOL questionnaires and
included patients treated with chemotherapy. It is not
clear whether these differences could explain the dis-
crepancies among results. Further studies in terms of the
effect of sleep on different domains/components of QOL
are warranted.Conclusions
This prospective longitudinal study provides a unique
perspective by only examining patients receiving RT
following lumpectomy. Our ﬁndings provide value for
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during, and up to 1 year post-RT, which is not a well-
studied treatment period. Overall, our study showed
that early breast cancer women’s QOL did not change
or decrease signiﬁcantly during or after RT. Instead,
patients’ role limitations resulting from physical health
improved at 1 year. Nevertheless, several risk factors for
poor QOL were identiﬁed, including increased BMI and
increased perceived stress. Future prospective studies
with a larger cohort are needed to substantiate our ﬁnd-
ings and design interventional trials to improve QOL in
breast cancer patients at risk for overall decreased QOL
during and after RT.References
1. Desantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013.
CA Cancer J Clin. 2014;64:52-62.
2. SEER Cancer Statistics Factsheets: Breast Cancer. Bethesda, MD:
National Cancer Institute; 2013.
3. Groenvold M. Health-related quality of life in early breast cancer.
Dan Med Bull. 2010;57:B4184.
4. Montazeri A. Health-related quality of life in breast cancer patients:
A bibliographic review of the literature from 1974 to 2007. J Exp
Clin Cancer Res. 2008;27:32.
5. Fang P, Tan KS, Troxel AB, et al. High body mass index is
associated with worse quality of life in breast cancer patients
receiving radiotherapy. Breast Cancer Res Treat. 2013;141:
125-133.
6. Fortner BV, Stepanski EJ, Wang SC, et al. Sleep and quality of
life in breast cancer patients. J Pain Symptom Manage. 2002;24:
471-480.
7. Hadi N, Soltanipour S, Talei A. Impact of modiﬁed radical mas-
tectomy on health-related quality of life in women with early stage
breast cancer. Arch Iran Med. 2012;15:504-507.
8. He ZY, Tong Q, Wu SG, et al. A comparison of quality of life and
satisfaction of women with early-stage breast cancer treated with
breast conserving therapy vs. mastectomy in southern China. Sup-
port Care Cancer. 2012;20:2441-2449.
9. Ivanauskiene R, Kregzdyte R, Padaiga Z. Evaluation of health-
related quality of life in patients with breast cancer. Medicina
(Kaunas). 2010;46:351-359.
10. Safarinejad MR, Shaﬁei N, Safarinejad S. Quality of life and sexual
functioning in young women with early-stage breast cancer 1 year
after lumpectomy. Psychooncology. 2013;22:1242-1248.
11. Darby S, McGale P, Correa C, et al. Effect of radiotherapy after
breast-conserving surgery on 10-year recurrence and 15-year
breast cancer death: Meta-analysis of individual patient data
for 10,801 women in 17 randomised trials. Lancet. 2011;378:
1707-1716.
12. Halkett GK, Kristjanson LJ, Lobb EA. ‘If we get too close to your
bones they’ll go brittle’: Women’s initial fears about radiotherapy
for early breast cancer. Psychooncology. 2008;17:877-884.
13. Badakhshi H, Gruen A, Sehouli J, et al. The impact of patient
compliance with adjuvant radiotherapy: A comprehensive cohort
study. Cancer Med. 2013;2:712-717.
14. Carver CS, Smith RG, Petronis VM, et al. Quality of life among
long-term survivors of breast cancer: Different types of antecedents
predict different classes of outcomes. Psychooncology. 2006;15:
749-758.
15. Ganz PA, Desmond KA, Leedham B, et al. Quality of life in long-
term, disease-free survivors of breast cancer: A follow-up study.
J Natl Cancer Inst. 2002;94:39-49.16. Imayama I, Alfano CM, Neuhouser ML, et al. Weight, inﬂammation,
cancer-related symptoms and health-related quality of life among
breast cancer survivors. Breast Cancer Res Treat. 2013;140:159-176.
17. ICRU. Prescribing, Recording, and Reporting Photon Beam Ther-
apy (Report 50); 1993.
18. McHorney CA, Ware Jr JE, Lu JF, et al. The MOS 36-item Short-
Form Health Survey (SF-36): III. Tests of data quality, scaling
assumptions, and reliability across diverse patient groups. Med
Care. 1994;32:40-66.
19. McHorney CA, Ware Jr JE, Raczek AE. The MOS 36-Item Short-
Form Health Survey (SF-36): II. Psychometric and clinical tests of
validity in measuring physical and mental health constructs. Med
Care. 1993;31:247-263.
20. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health
survey (SF-36). I. Conceptual framework and item selection. Med
Care. 1992;30:473-483.
21. Ganz PA, Kwan L, Stanton AL, et al. Physical and psychosocial
recovery in the year after primary treatment of breast cancer. J Clin
Oncol. 2011;29:1101-1109.
22. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported
symptoms and quality of life during treatment with tamoxifen or
raloxifene for breast cancer prevention: The NSABP Study of
Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:
2742-2751.
23. Ware JEJ. SF-36 Health Survey Manual and Interpretation Guide.
Boston, MA: The Health Institute; 1993.
24. Ware JEJ, Kosinski M. SF-36 Physical and Mental Health Summary
Scales: A Manual for Users of Version 1. 2nd ed. Lincoln, RI:
QualityMetric Incorporated; 2001.
25. Howard-Anderson J, Ganz PA, Bower JE, et al. Quality of life,
fertility concerns, and behavioral health outcomes in younger breast
cancer survivors: A systematic review. J Natl Cancer Inst. 2012;
104:386-405.
26. Liu L, Fiorentino L, Rissling M, et al. Decreased health-related
quality of life in women with breast cancer is associated with
poor sleep. Behav Sleep Med. 2013;11:189-206.
27. Buysse DJ, Reynolds 3rd CF, Monk TH, et al. The Pittsburgh Sleep
Quality Index: A new instrument for psychiatric practice and
research. Psychiatry Res. 1989;28:193-213.
28. Liu L, Fiorentino L, Natarajan L, et al. Pre-treatment symptom
cluster in breast cancer patients is associated with worse sleep, fa-
tigue and depression during chemotherapy. Psychooncology. 2009;
18:187-194.
29. Golden-Kreutz DM, Thornton LM, Wells-Di Gregorio S, et al.
Traumatic stress, perceived global stress, and life events: Prospec-
tively predicting quality of life in breast cancer patients. Health
Psychol. 2005;24:288-296.
30. Winzelberg AJ, Classen C, Alpers GW, et al. Evaluation of an
internet support group for women with primary breast cancer.
Cancer. 2003;97:1164-1173.
31. Cohen S, Kamarck T, Mermelstein R. A global measure of
perceived stress. J Health Soc Behav. 1983;24:385-396.
32. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in
health-related quality of life: The remarkable universality of half a
standard deviation. Med Care. 2003;41:582-592.
33. Schou I, Ekeberg O, Sandvik L, et al. Multiple predictors of health-
related quality of life in early stage breast cancer. Data from a year
follow-up study compared with the general population. Qual Life
Res. 2005;14:1813-1823.
34. Prescott RJ, Kunkler IH, Williams LJ, et al. A randomised
controlled trial of postoperative radiotherapy following breast-
conserving surgery in a minimum-risk older population. The
PRIME trial. Health Technol Assess. 2007;11:1-149. iii-iv.
35. Rayan G, Dawson LA, Bezjak A, et al. Prospective comparison of
breast pain in patients participating in a randomized trial of breast-
conserving surgery and tamoxifen with or without radiotherapy.
Int J Radiat Oncol Biol Phys. 2003;55:154-161.
16 C. Xiao et al Advances in Radiation Oncology: JanuaryeMarch 201636. Rahn AN, Mose S, Zander-Heinz A, et al. Inﬂuence of radiotherapy
on psychological health in breast cancer patients after breast
conserving surgery. Anticancer Res. 1998;18:2271-2273.
37. Freedman GM, Li T, Anderson PR, et al. Health states of women
after conservative surgery and radiotherapy for breast cancer. Breast
Cancer Res Treat. 2010;121:519-526.
38. Elme A, Utriainen M, Kellokumpu-Lehtinen P, et al. Obesity and
physical inactivity are related to impaired physical health of breast
cancer survivors. Anticancer Res. 2013;33:1595-1602.
39. Henderson VP, Clemow L, Massion AO, et al. The effects of
mindfulness-based stress reduction on psychosocial outcomes andquality of life in early-stage breast cancer patients: A randomized
trial. Breast Cancer Res Treat. 2012;131:99-109.
40. Hoffman CJ, Ersser SJ, Hopkinson JB, et al. Effectiveness of
mindfulness-based stress reduction in mood, breast- and
endocrine-related quality of life, and well-being in stage 0 to III
breast cancer: A randomized, controlled trial. J Clin Oncol. 2012;
30:1335-1342.
41. Sanford SD, Wagner LI, Beaumont JL, et al. Longitudinal pro-
spective assessment of sleep quality: before, during, and after
adjuvant chemotherapy for breast cancer. Support Care Cancer.
2013;21:959-967.
